Treatment with proton pump inhibitors as a cofactor in adverse reactions of patients undergoing oral food immunotherapy

Main Article Content

Marta García Vega
Sara Bellón Alonso
Amelia Pérez España
Sergio José Quevedo Teruel
Sonia Fernández Fernández
Teresa Bracamonte Bermejo
Luis Echeverría Zudaire


proton pump inhibitors, oral immunotherapy, cofactor, adverse reaction, anaphylaxis, food allergy


Background and objectives: Based on previous studies revealing acid-suppression medication as a risk factor for food allergy tolerance induction, we aimed to establish the importance of those findings in patients undergoing oral immunotherapy (OIT).
Materials and methods, results: We describe a case series of four patients who underwent milk OIT with a concomitant use of proton pump inhibitor (PPI) medication and who developed anaphylaxis after a known, previously tolerated dose of milk.
Conclusions: PPIs may act as a cofactor in patients undergoing OIT, triggering adverse reac-tions, irrespective of the PPI used or the dosage. It would be necessary to separate the admin-istration of drug from food intake.
Since OIT is a new form of treatment, long-term adverse events arising from PPI treatment and other possible triggers are still uncertain. Consequently, monitoring of patient must be prolonged over time. Additional investigations on the influence of different drugs in OIT main-tenance phase are required.

Abstract 39 | PDF Downloads 39 XML Downloads 0 HTML Downloads 1


1. Bidat E, Deschildre A, Lemoine A, Benoist G, Valleteau J, Tressol C, et al. Cow’s milk protein allergy: A practical guide to the reintroduction of cow’s milk proteins – When and how it should be reintroduced. Rev Fr Allergol. 2019;59:41–53.
2. Ronkainen J, Talley NJ, Aro P, Storskrubb T, Johansson SE, Lind T, et al. Prevalence of oesophageal eosinophils and eosinophilic oesophagitis in adults: The population-based Kalixanda study. Gut. 2007;56:615–20.
3. Kim JS, Nowak-Wegrzyn A, Sicherer AH, Noone S, Moshier EL, Sampson HA. Dietary baked milk accelerates the resolution of cow’s milk allergy in children. J Allergy Clin Immunol. 2011;128:125–31.
4. Lucendo AJ, Arias A, Tenias JM. Relation between eosinophilic esophagitis and oral immunotherapy for food allergy: A systematic review with meta-analysis. Ann Allergy Asthma Immunol. 2014;113:624–9.
5. Echeverría-Zudaire LA, Fernández-Fernández S, Rayo-Fernández A, Muñoz-Archidona C, Checa-Rodríguez R. Primary eosinophilic gastrointestinal disorders in children who have received food oral immunotherapy. Allergol Immunopathol. 2016;44(6):531–6.
6. Jordakieva, G., Kundi, M., Untersmayr, E. et al. Country-wide medical records infer increased allergy risk of gastric acid inhibition. Nat Commun. 2019;10:3298.
https://doi. org/10.1038/s41467-019-10914-6
7. Lucendo AJ, Molina-Infante J, Arias A, von Arnim U, Dredenoord AJ, Bussmann C, et al. Guidelines on eosinophilic esophagitis: Evidence-based statements and recommendations for diagnosis and management in children and adults. United European Gastroenterol J. 2017; 5:335–58.
8. Diesner SC, Knittelfelder R, Krishnamurthy D, Pali-Schöll I, Gajdzik L, Jensen-Jarolim E, et al. Dose-dependent food allergy induction against ovalbumin under acid-suppression: A murine food allergy model. Immunol Lett. 2008;121:45–51.
9. Imhann F, Bonder MJ, Vich Vila A, Fu J, Mujagic Z, Vork L, et al. Proton pump inhibitors affect the gut microbiome. Gut. 2016;65:740–8.
10. DeMuth K, Stecenko A, Sullivan K, Fitzpatrick A. Relationship between treatment with antacid medication and the prev-alence of food allergy in children. Allergy Asthma Proc. 2013;34:227–32.
11. Untersmayr E, Bakos N, Schöll I, Kundi M, Roth-Walter F, Szalai K, et al. Anti-ulcer drugs promote IgE formation toward dietary antigens in adult patients. FASEB J. 2005;19:656–8.
12. Samadi N, Klems M, Untersmayr E. The role of gastrointestinal permeability in food allergy. Ann Allergy Asthma Immunol. 2018;121:168–73.